BMS-212122

BMS-212122 is a highly potent small molecule inhibitor of microsomal triglyceride transfer protein (MTP), developed by Bristol Myers Squibb. It was designed as a benzimidazole-based analogue and is significantly more potent than earlier compounds such as BMS-201038 at reducing plasma lipids (cholesterol, VLDL/LDL, and triglycerides) in animal models including hamsters and cynomolgus monkeys. In preclinical studies, it demonstrated robust hypolipidemic effects and reduced atherosclerotic plaque lipid content and monocyte-derived (CD68+) cells. While primarily evaluated for metabolic and cardiovascular indications, there is no evidence that BMS-212122 entered clinical trials in humans; its use so far has been confined to exploratory research and preclinical experiments[1][3][5][7][9].

Other names

UNII-0Z473OO6GBUNII0Z473OO6GBUNII 0Z473OO6GB